Stockscreener 앱 받기
17.29
2.00%
0.3231
전일 마감가:
$16.97
열려 있는:
$17.31
하루 거래량:
481.66K
Relative Volume:
3.16
시가총액:
$1.70B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$16.81
$17.45
1주일 범위
$14.62
$18.12
52주 변동 폭
$14.62
$18.12
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
DFTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
17.30 | 1.67B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.81 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.12 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.70 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.33 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.01 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital - Investing.com
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's What Happened - MarketBeat
Definium Therapeutics Launches Educational LSD Campaign to Advance Psychedelic Psychiatry - TipRanks
Definium launches educational campaign on LSD for mental health - Investing.com
Definium launches educational campaign on LSD for mental health By Investing.com - Investing.com Nigeria
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care - Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Short Interest Update - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Recent Double Digit Share Price Returns - Yahoo Finance
Deinium Therapeutics (DFTX) Is Up 8.7% After Rebrand And DT120 Anxiety Pipeline UpdateWhat's Changed - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 1-Year 110% Surge? - Yahoo Finance
DFTX (Definium Therapeutics) Momentum Rank : 10 (As of Jan. 18, 2026) - GuruFocus
Assessing Mind Medicine (MindMed) (DFTX) Valuation After Rebrand To Deinium Therapeutics And Pipeline Progress - Sahm
Definium Therapeutics stock hits 52-week high at 15.3 USD By Investing.com - Investing.com Nigeria
Definium Therapeutics stock hits 52-week high at 15.3 USD - Investing.com
Five new option listings and one option delisting on January 15th - TipRanks
MNMD: DT120 targets rapid, lasting relief for anxiety and depression, with pivotal data due in 2024 - TradingView — Track All Markets
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 - Business Wire
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol "DFTX" Effective January 15, 2026 - Yahoo Finance
Mind Medicine Inc. will Change its Ticker to DFTX from MNMD - marketscreener.com
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD) - Sahm
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 5.6%Here's What Happened - MarketBeat
Definium Therapeutics Rebrands and Highlights 2026 Pipeline - TipRanks
Definium Therapeutics (MNMD) Announces Rebranding and Ticker Cha - GuruFocus
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Sells $339,151.65 in Stock - MarketBeat
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
MindMed Announces New Employee Inducement Grant - Business Wire
MindMed Reports Q3 2025 Financial Results and Business Updates - Business Wire
MindMed to Participate in Upcoming Investor Conferences - Business Wire
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares - Business Wire
MindMed to Report Q3 2025 Financial Results on November 6, 2025 - Business Wire
Mind Medicine says it announces pricing of $225 million public offering at $12.25 per share - marketscreener.com
Mind Medicine Nears Pivotal Year: Strong Fundamentals Make It A Buy (NASDAQ:MNMD) - Seeking Alpha
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today - The Motley Fool
Mind Medicine stock upgraded at Oppenheimer (MNMD:NASDAQ) - Seeking Alpha
Mind Medicine Inc.(NasdaqGS: MNMD) added to Russell 3000 Value Index - marketscreener.com
MindMed to Participate in June Investor Conferences - marketscreener.com
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer - marketscreener.com
MindMed Announces New Employee Inducement Grants - marketscreener.com
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference - marketscreener.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - marketscreener.com
Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - marketscreener.com
MindMed Appoints Matt Wiley as Chief Commercial Officer - marketscreener.com
MindMed to Present at Leerink's Global Healthcare Conference 2025 - marketscreener.com
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - marketscreener.com
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call (MNMD) - Seeking Alpha
MindMed to Be Added to the Nasdaq Biotechnology Index - marketscreener.com
Mind Medicine: No News = Good News (NASDAQ:MNMD) - Seeking Alpha
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate (NASDAQ:MNMD) - Seeking Alpha
Definium Therapeutics Inc (DFTX) 재무 분석
Definium Therapeutics Inc (DFTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.39%
1.60%
자본화:
|
볼륨(24시간):